T&R Biofab Co. (246710.KQ) stock: Winston Score, insiders and Congress trades

T&R Biofab is a South Korean company that works in the field of bioprinting and regenerative medicine. It develops technology to print living tissue and organs using biological materials, sometimes called "bioinks." Its main customers include hospitals, research institutions, and pharmaceutical companies that need tissue models for medical research and drug testing. The company earns revenue by selling bioprinting equipment, bioink materials, and related research services. It operates primarily in South Korea but aims to expand into global medical and research markets. With a market capitalization of roughly $64.6 billion, it is a notable player in the emerging bioprinting space, though its negative operating margin shows it is still spending heavily to develop and commercialize its technology. The key growth driver is the long-term potential for printed tissues and organs to replace animal testing and, eventually, address organ shortages — but the main risk is that this science remains largely experimental, meaning commercial scale and regulatory approval could take many years.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-10.